Wealthfront Advisers LLC Purchases Shares of 9,554 Alnylam Pharmaceuticals, Inc. $ALNY

Wealthfront Advisers LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 9,554 shares of the biopharmaceutical company’s stock, valued at approximately $2,876,000.

Several other large investors have also modified their holdings of the stock. First Horizon Corp boosted its position in shares of Alnylam Pharmaceuticals by 20.7% in the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 28 shares during the last quarter. Daiwa Securities Group Inc. increased its position in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares during the last quarter. Golden State Wealth Management LLC increased its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the last quarter. Coldstream Capital Management Inc. raised its stake in Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 38 shares during the period. Finally, Atlantic Union Bankshares Corp raised its stake in Alnylam Pharmaceuticals by 20.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 40 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: BMO Capital Markets upgraded Alnylam to “strong buy”, following its initiation of coverage with an “outperform” rating and a $318 price target. The bullish view could support investor confidence by indicating substantial potential upside from recent trading levels. Benzinga analyst coverage report TickerReport Alnylam coverage

Alnylam Pharmaceuticals Trading Down 5.5%

Shares of ALNY stock opened at $229.30 on Friday. The stock has a market cap of $30.68 billion, a price-to-earnings ratio of 42.62 and a beta of 0.30. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The firm’s 50 day moving average price is $267.95 and its two-hundred day moving average price is $297.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the previous year, the firm earned ($0.51) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 66.9% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ALNY. Bank of America decreased their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Royal Bank Of Canada dropped their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. HC Wainwright cut their target price on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Sanford C. Bernstein upgraded Alnylam Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Finally, Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research report on Friday, July 31st. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.62.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.